Diabetes Tsunami? China Eyes More Modern Therapies Under 2025 Plan
Diabetes poses a triple whammy and is likely to cripple China's health care system in near future. To counter, the Chinese government looks at total disease management, long-acting insulins and GLP-1 products.
You may also be interested in...
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.